27th Jul 2020 21:19
RTW Venture Fund Ltd - life sciences-focused investment firm - Notes that portfolio company iTeos Therapeutics Inc has priced its NASDAQ initial public offering at USD201.1 million. ITeos is a clinical-stage biotechnology developing innovative cancer immunotherapies. IPO was oversubscribed, raising USD201.1 million by issuing 10.5 million shares at USD19.00 each.
Current stock price: USD1.48
Year-to-date change: up 8.0%
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Rtw Biotech